

GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Gastroesophageal reflux disease (GERD) is an extremely common condition, affecting nearly one in five U.S. adults at least weekly and nearly one in ten daily.[1-3] It affects women more commonly than men, and the peak ages are from 30 to 60.[4]

Symptoms of GERD occur due to esophageal irritation from acidic stomach contents (including pepsin and sometimes bile acids) contacting the esophagus through the lower esophageal sphincter (LES).

A variety of symptoms can occur:

- Retrosternal discomfort (e.g. pain, burning)
- Acid regurgitation
- Nausea and/or vomiting
- Laryngitis
- Cough
- Dental erosions
- Wheezing
- Difficulty swallowing

Normally, the LES only relaxes when one is swallowing food. Otherwise, it has enough tone to limit retrograde flow of acidic contents into the esophagus. With long-term acid exposure, the esophagus may become inflamed (esophagitis) and constrict (stricture), and it can also develop columnar metaplasia (Barrett's esophagus) or adenocarcinoma.

There are many factors that cause GERD, and these should be systematically evaluated when creating a treatment plan that aims to *cure* rather than just *treat* this disease. The quality of life burden is significant and may be greater than that of congestive heart failure, coronary heart disease, and diabetes.[5]

Although the LES itself may appear to be the site of dysfunction, it may not play the primary role in GERD pathogenesis. The problem may be downstream, due to increased intra-abdominal pressure (e.g. from obesity, pregnancy, restrictive clothing, ascites). It may also be caused by poor GI motility (gastroparesis) or from forces that challenge normal forward motility (recumbent position, bending over). It may also be due to compromised esophageal mucosal barrier (e.g. from low saliva production). This etiology is often overlooked; one study showed that when acid is infused directly into the esophagus, 88% of those with GERD were symptomatic, whereas only 15% of controls without known GERD had symptoms.[6]

Studies using proton pump inhibitors (PPIs) and histamine-2 (H2) antagonists show significant benefits in their placebo groups. This supports the notion that the mind has significant potential to affect GERD symptoms. In a large meta-analysis, placebo rates averaged about 20% for pharmaceuticals, indicating that any GERD intervention that one expects benefit will provide a positive response for one in five people independent of the

mechanism of action. Creating this positive expectation through a therapeutic clinical relationship can therefore be an important aspect of developing a Personal Health Plan (PHP).

ROLE OF PREVENTION AND SCREENING

Primary prevention of GERD should be based on health screening and prevention recommendations that apply to all Veterans. Perhaps the most important of these include maintaining a healthy weight, avoiding tobacco products, and limiting excess alcohol consumption. In those with a previous personal history or family history of GERD, it may also be prudent to avoid potentially provocative medications, when possible. These include:

- Aminophylline
- Anticholinergics
- Beta-adrenergics
- Calcium channel blockers
- Nitrates
- Phosphodiesterase inhibitors including sildenafil

DIETARY SUPPLEMENTS

Note: Please refer to the [Passport to Whole Health](#), Chapter 15 on Dietary Supplements for more information about how to determine whether or not a specific supplement is appropriate for a given individual. Supplements are not regulated with the same degree of oversight as medications, and it is important that clinicians keep this in mind. Products vary greatly in terms of accuracy of labeling, presence of adulterants, and the legitimacy of claims made by the manufacturer.

DEGLYCYRRHIZINATED LICORICE (*GLYCYRRHIZA GLABRA*)

Dose: 2-4 380 milligrams lozenges before meals.[7] This botanical medicine, like several others on this list, is a demulcent (or mucilaginous). It enhances esophageal mucosal protection. The deglycyrrhizinated form of licorice (DGL), as the name implies, does not contain glycyrrhizin, which has mineralocorticoid actions, such as hypertension, hypokalemia, and edema.[8] Do not use tablets. Rather, use the lozenges, as they can be chewed and swallowed slowly to allow effective contact with the lower esophagus.

SLIPPERY ELM (*ULMUS FULVA*)

Dose: 1-2 tablespoon(s) powder mixed with 1 cup water after meals and before bedtime. Slippery Elm is also a demulcent that is useful for GERD. The root bark powder needs to be carefully titrated with water to ensure a palatable consistency. To enhance flavor, consider

adding a small amount of honey or maple syrup. This herb has an excellent safety profile, though it has the potential to bind to certain medications and decrease their absorption.[8]

MARSHMALLOW (ALTHEA OFFICINALIS)

Dose: 2-3 teaspoon(s), in divided doses, as an infusion of leaves or root.[9] This is another mucilaginous herb with similar properties to slippery elm. Again, this may inhibit the absorption of some medications.[8]

CHAMOMILE (MATRICARIA RECUTITA)

Dose: 1 tablespoon dried flowers per cup hot water as a tea 3-4 times daily.[10] This botanical has antispasmodic effects on the GI tract, but its use for GERD likely comes from its anti-inflammatory effects.[8] Be mindful if one has allergies to plants in the daisy family (Asteraceae), as there may be some cross-reactivity.

OTHER SYSTEMS

Traditional Chinese medicine (TCM) provides a comprehensive diagnostic and therapeutic framework for treating individuals with diseases such as GERD through lifestyle changes, botanical medicines, and other modalities, such as acupuncture.

Acupuncture may have clinical efficacy for GERD based on three possible mechanisms. Acupuncture may *stimulate GI motility* and *decrease acid secretion* via the vagus nerve and other parasympathetic pathways. Also, acupuncture may *increase esophageal sensory thresholds*, which are known to be decreased in those with GERD. Although only a few studies have investigated the clinical effectiveness of acupuncture on relieving GERD symptoms, several have shown that this modality has predictable effects on GI motility, acid secretion, and pain thresholds in healthy volunteers.[6,11,12] One study involving 60 patients showed that weekly acupuncture was equivalent to a pharmacologic regimen of omeprazole and mosapride after 6 weeks of treatment on both subjective and objective measures.[13] Acupuncture may also be more effective than doubling the dose of a PPI in those with persistent symptoms on standard-dose PPIs.[14]

Acupuncture should be considered based on one's preferences, if it is easily and widely available, and/or if allopathic treatments have proven ineffective. It may also be a valuable tool in helping one to wean off of a proton-pump inhibitor (please refer to the section below).

A NOTE ABOUT CHRONIC PPI USE

Although pharmaceuticals can be very effective in relieving GERD symptoms, there are increasing concerns of the harmful effects of chronic acid suppression. In our attempts to balance risks and benefits, and to "first do no harm," these observations should be

routinely considered when deciding whether to continue chronic acid suppression therapies:

DIGESTION

Incomplete digestion of protein. Proteins begin to be digested in our stomach directly by hydrochloric acid and indirectly through hydrochloric acid's activation of pepsin. Pepsin levels fall within a few days of starting a PPI. One hypothesis that may explain increasing rates of eosinophilic esophagitis is that the esophageal immune system is reacting to more incompletely digested proteins due to decreased activation of pepsin.[15,16]

Decreased absorption of B12,[17,18] iron (especially nonheme),[19,20] and calcium.[21] Hydrochloric acid often plays a role in removing vitamins from their carrier proteins, making these accessible for assimilation into our body.

IMMUNITY

Increases in community-acquired Clostridium difficile infection. In one large case-control study, use of PPI and H2-antagonists at least doubled rates of this infection (4% absolute increase with H2-antagonist, 15% absolute increase with PPI).[22]

Increases in community-acquired pneumonia. In adults, a large cohort study showed one increased case in 226 of those treated with PPIs and 508 of those treated with H2-antagonists.[23] In children, the rate of pneumonia is 10 times higher for those on these medications.[24]

Increases in acute gastroenteritis in children. Many children are now being treated for reflux-type symptoms. After 2 months of use in young children aged 4-36 months, their risk of developing gastroenteritis more than doubles.[24]

CANCER

Enterochromaffin cell hyperplasia. Chronic acid suppression causes an adaptive increase secretion of gastrin as the body attempts to restore normal gastric acidity. This leads to a hypergastrinemic state that has been shown to be a risk factor for tumor development.[25]

Increased gastric carcinogens. Lower gastric acidity equates to increased gastric bacterial load. One hypothesis is that this environment may lead to increased conversion of dietary nitrates to nitrites. The nitrites are then converted to the carcinogenic compound N-nitrosamine.

FRACTURES

Associations with long-term acid suppression have been found for **hip[26,27] and spine[28,29] fractures.** This may be related to impaired calcium absorption, as described above.

Many clinicians place people with GERD on medications with no real thought given to underlying causes, which end up never being addressed. Some patients may try to discontinue PPI therapy on their own, only to have a sudden return of symptoms. However, this return of symptoms may be predictable and not necessarily indicative of continuing GERD pathology. When *healthy and asymptomatic* people are given 40 milligrams of pantoprazole for 6 weeks, they will get 10-14 days of GERD symptoms when they stop therapy.




Figure 1. Symptoms of reflux in people without GERD when taking PPIs versus placebo.¹ Blue, dashed = Took PPI; Red, solid = Placebo group. Reprinted by permission from Macmillan Publishers LTD: American Journal of Gastroenterology, copyright 2010.

TAPERING OFF A PPI

After someone has made appropriate lifestyle changes, and after underlying causes have been addressed, it may be appropriate to taper off his or her PPI. Rather than simply decreasing the dose over 2-4 weeks, a *combination of modalities* should be added to maximize one's chances for success. For more information, refer to "[Coming Off a Proton Pump Inhibitor.](#)"

SUMMARY OF NONPHARMACEUTICAL OPTIONS FOR GERD

Based on the Strength of Recommendation Taxonomy (SORT) criteria, there are no known non-pharmaceutical therapies for GERD with consistent, good-quality, and patient-oriented evidence. To receive an "A" rating, a therapy needs to be supported by a systematic review or meta-analysis showing benefit, a Cochrane review with clear recommendation, or a high-quality, patient-oriented randomized controlled trial. The following therapies are based on inconsistent or limited-quality, patient-oriented evidence and would receive a "B" rating:

- Nearly daily moderate to vigorous exercise for 30-60 minutes, away from mealtime
- Food elimination diet
- Increase fiber to meet general recommendations

- Elevate head of bed (consider only in those with severe symptoms)
- Acupuncture
- Abdominal breathing

The following therapies are based on consensus, usual practice, opinion, disease-oriented evidence or case series and would receive a “C” rating:

- Botanicals (licorice/DGL, slippery elm, marshmallow, chamomile)
- Relaxation techniques (e.g. meditation, journaling)

AUTHOR(S)

“Gastroesophageal Reflux Disease” was written by [David Lessens](#), MD, MPH (2014). Sections were adapted from “Gastroesophageal Reflux Disease” by [David Kiefer](#), MD, [David Rakel](#), MD, and [Rian Podein](#), MD.

This Whole Health tool was made possible through a collaborative effort between the University of Wisconsin Integrative Health Program, VA Office of Patient Centered Care and Cultural Transformation, and Pacific Institute for Research and Evaluation.

REFERENCES

1. Goyal R. Diseases of the Esophagus. In: Kasper DL, Harrison TR, eds. *Harrison's Principles of Internal Medicine*. New York: McGraw-Hill, Medical Pub. Division; 2005.
2. Wileman SM, McCann S, Grant AM, Krukowski ZH, Bruce J. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. *Cochrane Database Syst Rev*. 2010(3):Cd003243.
3. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. *N Engl J Med*. 2008;359(16):1700-1707.
4. Gastroesophageal reflux disease (GERD). Updated October 14, 2103; In: *DynaMed*. EBSCO Information Services. <http://web.ebscohost.com/dynamed/>. Accessed November 25, 2013.
5. Heidelbaugh J. Gastroesophageal reflux disease. Updated August 27, 2013; In: *Essential Evidence Plus*. Hoboken (NJ): John Wiley & Sons, Inc., 2013. <http://www.essentialevidenceplus.com/content/eee/192>. Accessed November 25, 2013.
6. Takahashi T. Acupuncture for functional gastrointestinal disorders. *J Gastroenterol*. 2006;41(5):408-417.
7. Johnson LP. *Pocket Guide to Herbal Remedies*. Malden, Mass.: Blackwell Science; 2002.
8. Brinker FJ. *Herbal Contraindications and Drug Interactions Plus Herbal Adjuncts with Medicines*. Sandy, OR: Eclectic Medical Publications; 2010.
9. Festi D, Scaioli E, Baldi F, et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. *World J Gastroenterol*. 2009;15(14):1690-1701.

10. Johnson T, Gerson L, Hershcovici T, Stave C, Fass R. Systematic review: the effects of carbonated beverages on gastro-oesophageal reflux disease. *Aliment Pharmacol Ther.* 2010;31(6):607-614.
11. Yin J, Chen JD. Gastrointestinal motility disorders and acupuncture. *Auton Neurosci.* 2010;157(1-2):31-37.
12. Takahashi T. Effect and mechanism of acupuncture on gastrointestinal diseases. *Int Rev Neurobiol.* 2013;111:273-294.
13. Zhang CX, Qin YM, Guo BR. Clinical study on the treatment of gastroesophageal reflux by acupuncture. *Chin J Integr Med.* 2010;16(4):298-303.
14. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. *Aliment Pharmacol Ther.* 2007;26(10):1333-1344.
15. Maltby EJ. The digestion of beef proteins in the human stomach. *J Clin Invest.* 1934;13(2):193-207.
16. Orel R, Turk H. Re: Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? *Am J Gastroenterol.* 2010;105(2):468; author reply 469.
17. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). *Ann Intern Med.* 1994;120(3):211-215.
18. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. *J Clin Epidemiol.* 2004;57(4):422-428.
19. Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. *Gastroenterology.* 1981;81(6):1068-1071.
20. Sharma VR, Brannon MA, Carlross EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. *South Med J.* 2004;97(9):887-889.
21. Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. *Ann Intern Med.* 1967;66(5):917-923.
22. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA.* 2005;294(23):2989-2995.
23. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA.* 2004;292(16):1955-1960.
24. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. *Pediatr Neonatol.* 2006;117(5):e817-820.
25. Waldum HL, Gustafsson B, Fossmark R, Qvigstad G. Antiulcer drugs and gastric cancer. *Dig Dis Sci.* 2005;50 Suppl 1:S39-44.
26. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. *Gastroenterology.* 2010;139(1):93-101.
27. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. *Arch Intern Med.* 2010;170(9):765-771.

28. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. *Bone*. 2011;48(4):768-776.
29. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. *Am J Gastroenterol*. 2009;104:S2-S4.